The advent of ctDNA has the potential to be a game changer in some cancers, but limited data is available in oesophago-gastric cancers (OGC). The prognostic value of ctDNA and the potential for false positive results due to clonal haematopoiesis of indeterminate potential (CHIP) was recently reported in operable OGC.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $4.96 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 545, 446–451 (2017).
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S., Moore, K. L., Joshi, S. S. et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin. Cancer Res. 25, 7098–7112 (2019).
Leal, A., van Grieken, N. C., Palsgrove, D. N., Phallen, J., Medina, J. E., Hruban, C. et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat. Commun. 11, 1–1 (2020).
Christensen, E., Birkenkamp-Demtröder, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clini. Oncol. 37, 1547–1557 (2019).
Ococks E., Frankell A. M., Soler N. M., Grehan N., Northrop A., Coles H. et al. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann. Oncol. 32, 522–532 (2021).
Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 25, 1928–1937 (2019).
Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S. et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat. Genet. 51, 506–516 (2019).
Wasserman, I., Lee, L. H., Ogino, S., Marco, M. R., Wu, C., Chen, X. et al. SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance. Clin. Cancer Res. 25, 1948–1956 (2019).
CRUK. Cancer Statistics (2021).
Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).
Smyth, E. C., Fassan, M., Cunningham, D., Allum, W. H., Okines, A. F., Lampis, A. et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J. Clin. Oncol. 34, 2721 (2016).
We acknowledge the patients who kindly agreed to take part on the Ococks et al. study.
Ethics approval and consent to participate
This manuscript is based on published data, therefore ethical approval and consent is not applicable.
The data mentioned on this manuscript is fully available online. Any further information not provided should be discussed with the corresponding authors of each cited paper.
Bruno de Paula declares personal consultancy fees and/or travel in the past 5 years from: Roche and Pfizer Elizabeth Smyth declares personal consultancy fees and/or travel in the past 5 years from: Aptitude Health, Astra Zeneca, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Roche, Sai-Med, Servier, Zymeworks.
There was no funding for this manuscript.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
De Paula, B., C Smyth, E. Personalising care in oesophageal cancer care with liquid biopsy. Br J Cancer 125, 1036–1038 (2021). https://doi.org/10.1038/s41416-021-01370-5